Sandoz bags US epinephrine
Executive Summary
Sandoz has acquired exclusive distribution and commercialisation rights in the US to Adamis Pharamceuticals’ Symjepi (epinephrine) subcutaneous injectable, a non-substitutable alternative to Mylan’s EpiPen anaphylaxis treatment. The deal covers both an approved 0.3mg strength as well as a 0.15mg version that is pending US Food and Drug Administration (FDA) approval, while Sandoz also has “first right of negotiation” to acquire commercial rights outside of the US.